 Immunocompromised Host
"Immunocompromised Host" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
| Descriptor ID |
D016867
|
| MeSH Number(s) |
G12.470
|
| Concept/Terms |
Immunocompromised Host- Immunocompromised Host
- Host, Immunocompromised
- Hosts, Immunocompromised
- Immunocompromised Hosts
- Immunocompromised Patient
- Immunocompromised Patients
- Patient, Immunocompromised
- Patients, Immunocompromised
- Immunosuppressed Host
- Host, Immunosuppressed
- Hosts, Immunosuppressed
- Immunosuppressed Hosts
|
Below are MeSH descriptors whose meaning is more general than "Immunocompromised Host".
Below are MeSH descriptors whose meaning is more specific than "Immunocompromised Host".
This graph shows the total number of publications written about "Immunocompromised Host" by people in this website by year, and whether "Immunocompromised Host" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 2 | 2 | | 1999 | 3 | 1 | 4 | | 2000 | 1 | 4 | 5 | | 2001 | 1 | 0 | 1 | | 2003 | 4 | 2 | 6 | | 2004 | 0 | 4 | 4 | | 2005 | 3 | 3 | 6 | | 2006 | 2 | 3 | 5 | | 2007 | 0 | 4 | 4 | | 2008 | 4 | 3 | 7 | | 2009 | 5 | 1 | 6 | | 2010 | 2 | 1 | 3 | | 2011 | 3 | 6 | 9 | | 2012 | 3 | 1 | 4 | | 2013 | 2 | 3 | 5 | | 2014 | 3 | 3 | 6 | | 2015 | 2 | 6 | 8 | | 2016 | 3 | 4 | 7 | | 2017 | 2 | 4 | 6 | | 2018 | 7 | 5 | 12 | | 2019 | 5 | 8 | 13 | | 2020 | 3 | 6 | 9 | | 2021 | 5 | 2 | 7 | | 2022 | 1 | 3 | 4 | | 2024 | 0 | 3 | 3 | | 2025 | 2 | 1 | 3 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunocompromised Host" by people in Profiles.
-
Schapiro S, Pulciano N, Galindo-Ramirez J, Rau N, Tuells J, Agudelo Higuita NI, Thompson GR, Chastain DB, Henao-Martínez AF. Epidemiology and Outcomes of Sporotrichosis: A Descriptive Real-World Analysis From a Global Cohort. Mycoses. 2026 Feb; 69(2):e70152.
-
Chastain DB, Thompson GR, Henao-Martínez AF. Glucocorticoids, Concomitant Immunosuppression, and Pneumocystis jirovecii Pneumonia Prophylaxis Among US Adults. Clin Infect Dis. 2025 Dec 24; 81(5):1015-1018.
-
Klein JC, Shahwan KT, Petric UB, Mallela T, Voller L, Ruiz E, Ran N, Granger EE, Koyfman S, Vidimos A, Wysong A, Hirotsu K, Carucci JA, Carter JB, Cañueto J, Girardi FM, Mangold AR, Brodland DG, Zitelli JA, Willenbrink TJ, Lotter W, Jeanselme V, Nikahd M, Nijhawan RI, Srivastava D, Carr DR. Impact of immunosuppression on cutaneous squamous cell carcinoma outcomes. J Am Acad Dermatol. 2026 01; 94(1):151-160.
-
Kunz Coyne AJ, Alosaimy S, Lucas K, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang-Birken SL, Hobbs ALV, Agee J, Perkins NB, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Zhao JJ, Witucki P, Rybak MJ. Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes. Microbiol Spectr. 2025 Oct 07; 13(10):e0056525.
-
Scherger SJ, Molina KC, Palestine AG, Pecen PE, Bajrovic V. Cytomegalovirus Retinitis in the Modern Era of Solid Organ Transplantation. Transplant Proc. 2024 Sep; 56(7):1696-1701.
-
Henao-Martínez AF, Olivo Freites C, Agudelo Higuita NI, Marcos LA, Chastain DB, Mohareb AM, Tuells J, Villalpando-Carrion S, Franco-Paredes C. Clinical Characteristics and Outcomes of Disseminated Strongyloidiasis in the United States-A Multicenter Network Analysis. Am J Trop Med Hyg. 2024 Jul 03; 111(1):89-92.
-
Bergin SP, Chemaly RF, Dadwal SS, Hill JA, Lee YJ, Haidar G, Luk A, Drelick A, Chin-Hong PV, Benamu E, Khawaja F, Nanayakkara D, Papanicolaou GA, Small CB, Fung M, Barron MA, Davis T, McClain MT, Maziarz EK, Madut DB, Bedoya AD, Gilstrap DL, Todd JL, Barkauskas CE, Bigelow R, Leimberger JD, Tsalik EL, Wolf O, Mughar M, Hollemon D, Duttagupta R, Lupu DS, Bercovici S, Perkins BA, Blauwkamp TA, Fowler VG, Holland TL. Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Patients With Pneumonia: A Prospective Observational Study. Clin Infect Dis. 2024 03 20; 78(3):775-784.
-
Mancon A, Rizzo A, Mileto D, Grosso S, Foschi A, Cutrera M, Capetti A, Faggion I, Anselmo A, Monte A, Fillo S, Rizzardini G, Gismondo MR, Micheli V. Viro-immunological evaluation in an immunocompromised patient with long-lasting SARS-CoV-2 infection. Emerg Microbes Infect. 2022 Dec; 11(1):786-789.
-
Gualano B, Lemes ÍR, da Silva RP, Pinto AJ, Mazzolani BC, Smaira FI, Sieczkowska SM, Aikawa NE, Pasoto S, Medeiros-Ribeiro AC, Saad C, Yuk E, Silva C, Swinton P, Hallal PC, Roschel H, Bonfa E. Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients. Scand J Med Sci Sports. 2022 Oct; 32(10):1510-1515.
-
Gualano B, Saad CGS, Sieczkowska SM, Lemes ÍR, da Silva RP, Pinto AJ, Mazzolani BC, Smaira FI, Gil S, Oliveira-Junior G, Aikawa NE, Medeiros-Ribeiro AC, Silva CA, Yuki EFN, Pasoto SG, Pereira RMR, Shinjo SK, Andrade DCO, Sampaio-Barros PD, Roschel H, Bonfa E. Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients. J Appl Physiol (1985). 2022 03 01; 132(3):682-688.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|